CORMEDIX INC. Increase (Decrease) in Accounts Receivable
CORMEDIX INC. (CRMD) reported Increase (Decrease) in Accounts Receivable of -$10.01 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsReceivable · last filed 2026-08-13
- CORMEDIX INC. increase (decrease) in accounts receivable for the quarter ending 2026-06-30 was $6.43M.
- CORMEDIX INC. increase (decrease) in accounts receivable for the quarter ending 2026-03-31 was -$16.45M, a 654.64% decline year-over-year.
- CORMEDIX INC. increase (decrease) in accounts receivable for the quarter ending 2025-12-31 was $12.40M, a 63.97% decline year-over-year.
- CORMEDIX INC. increase (decrease) in accounts receivable for the quarter ending 2025-09-30 was $87.27M, a 407.94% increase year-over-year.
- CORMEDIX INC. increase (decrease) in accounts receivable for fiscal 2025 was $90.92M, a 75.56% increase from fiscal 2024.
- CORMEDIX INC. increase (decrease) in accounts receivable for fiscal 2024 was $51.79M.
- CORMEDIX INC. increase (decrease) in accounts receivable for fiscal 2019 was -$10.63K.
- CORMEDIX INC. increase (decrease) in accounts receivable for fiscal 2018 was -$51.99K, a 209.22% decline from fiscal 2017.
| Period end | Increase (Decrease) in Accounts Receivable 3 month | Increase (Decrease) in Accounts Receivable 3 month as first filed | Increase (Decrease) in Accounts Receivable 6 month | Increase (Decrease) in Accounts Receivable 6 month as first filed | Increase (Decrease) in Accounts Receivable 9 month | Increase (Decrease) in Accounts Receivable 12 month | Increase (Decrease) in Accounts Receivable 12 month as first filed | Increase (Decrease) in Accounts Receivable 89 month | Increase (Decrease) in Accounts Receivable 92 month |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $6.43M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | -$10.01M 10-Q · filed 2026-08-13 | $2.38M derived: sum of 3 quarters · filed 2026-08-13 | $89.65M derived: sum of 4 quarters · filed 2026-08-13 | |||||
| 2026-03-31 | -$16.45M 10-Q · filed 2026-05-14 | -$4.05M derived: sum of 2 quarters · filed 2026-05-14 | $83.22M derived: sum of 3 quarters · filed 2026-05-14 | $71.51M derived: sum of 4 quarters · filed 2026-08-13 | |||||
| 2025-12-31 | $12.40M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $99.67M derived: sum of 2 quarters · filed 2026-03-05 | $87.96M derived: sum of 3 quarters · filed 2026-08-13 | $90.92M 10-K · filed 2026-03-05 | |||||
| 2025-09-30 | $87.27M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $75.56M derived: sum of 2 quarters · filed 2026-08-13 | $78.53M 10-Q · filed 2025-11-12 | $112.93M derived: sum of 4 quarters · filed 2026-08-13 | |||||
| 2025-06-30 | -$11.71M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | -$8.74M 10-Q · filed 2026-08-13 | -$8.74M 10-Q · filed 2025-08-07 | $25.66M derived: sum of 3 quarters · filed 2026-08-13 | $42.84M derived: sum of 4 quarters · filed 2026-08-13 | ||||
| 2025-03-31 | $2.96M 10-Q · filed 2026-05-14 | $2.96M 10-Q · filed 2025-05-06 | $37.37M derived: sum of 2 quarters · filed 2026-05-14 | $54.55M derived: sum of 3 quarters · filed 2026-05-14 | |||||
| 2024-12-31 | $34.40M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $51.58M derived: sum of 2 quarters · filed 2026-03-05 | $51.79M 10-K · filed 2026-03-05 | $51.79M 10-K · filed 2025-03-25 | |||||
| 2024-09-30 | $17.18M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $17.39M 10-Q · filed 2025-11-12 | |||||||
| 2024-06-30 | $206.34K 10-Q · filed 2025-08-07 | ||||||||
| 2019-12-31 | -$4.00K derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-16 | $97.00 derived: sum of 2 quarters · filed 2020-03-16 | -$34.61K derived: sum of 3 quarters · filed 2020-03-16 | -$10.63K 10-K · filed 2020-03-16 | |||||
| 2019-09-30 | $4.09K derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-14 | -$30.62K derived: sum of 2 quarters · filed 2019-11-14 | -$6.63K 10-Q · filed 2019-11-14 | -$305.94K derived: sum of 4 quarters · filed 2020-03-16 | |||||
| 2019-06-30 | -$34.71K derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-14 | -$10.73K 10-Q · filed 2019-08-14 | -$310.03K derived: sum of 3 quarters · filed 2020-03-16 | -$1.49K derived: sum of 4 quarters · filed 2020-03-16 | |||||
| 2019-03-31 | $23.98K 10-Q · filed 2019-05-13 | -$275.32K derived: sum of 2 quarters · filed 2020-03-16 | $33.22K derived: sum of 3 quarters · filed 2020-03-16 | $29.18K derived: sum of 4 quarters · filed 2020-03-16 | |||||
| 2018-12-31 | -$299.30K derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-16 | $9.23K derived: sum of 2 quarters · filed 2020-03-16 | $5.20K derived: sum of 3 quarters · filed 2020-03-16 | -$51.99K 10-K · filed 2020-03-16 | |||||
| 2018-09-30 | $308.54K derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-14 | $304.50K derived: sum of 2 quarters · filed 2019-11-14 | $247.32K 10-Q · filed 2019-11-14 | $223.31K derived: sum of 4 quarters · filed 2019-11-14 | |||||
| 2018-06-30 | -$4.04K derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-14 | -$61.22K 10-Q · filed 2019-08-14 | -$85.23K derived: sum of 3 quarters · filed 2019-08-14 | -$146.74K derived: sum of 4 quarters · filed 2019-08-14 | |||||
| 2018-03-31 | -$57.18K 10-Q · filed 2019-05-13 | -$81.19K derived: sum of 2 quarters · filed 2019-05-29 | -$142.70K derived: sum of 3 quarters · filed 2019-05-29 | -$73.09K derived: sum of 4 quarters · filed 2019-05-29 | |||||
| 2017-12-31 | -$24.01K derived: 10-K 12 month − 10-Q 9 month · filed 2019-05-29 | -$85.52K derived: sum of 2 quarters · filed 2019-05-29 | -$15.91K derived: sum of 3 quarters · filed 2019-05-29 | $47.60K 10-K · filed 2019-05-29 | |||||
| 2017-09-30 | -$61.51K derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-14 | $8.10K derived: sum of 2 quarters · filed 2018-11-14 | $71.61K 10-Q · filed 2018-11-14 | $65.01K derived: sum of 4 quarters · filed 2018-11-14 | |||||
| 2017-06-30 | $69.61K derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-14 | $133.12K 10-Q · filed 2018-08-14 | $126.51K derived: sum of 3 quarters · filed 2018-08-14 | $142.38K derived: sum of 4 quarters · filed 2018-08-14 | |||||
| 2017-03-31 | $63.51K 10-Q · filed 2018-05-15 | $56.90K derived: sum of 2 quarters · filed 2018-05-15 | $72.77K derived: sum of 3 quarters · filed 2018-05-15 | -$259.76K derived: sum of 4 quarters · filed 2018-05-15 | |||||
| 2016-12-31 | -$6.61K derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-19 | $9.26K derived: sum of 2 quarters · filed 2018-03-19 | -$323.27K derived: sum of 3 quarters · filed 2018-03-19 | -$307.77K 10-K · filed 2018-03-19 | |||||
| 2016-09-30 | $15.86K derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-09 | -$316.67K derived: sum of 2 quarters · filed 2017-11-09 | -$301.17K 10-Q · filed 2017-11-09 | -$103.16K derived: sum of 4 quarters · filed 2017-11-09 | |||||
| 2016-06-30 | -$332.53K derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-09 | -$317.03K 10-Q · filed 2017-08-09 | -$119.03K derived: sum of 3 quarters · filed 2017-08-09 | -$108.81K derived: sum of 4 quarters · filed 2017-08-09 | |||||
| 2016-03-31 | $15.50K 10-Q · filed 2017-05-10 | $213.51K derived: sum of 2 quarters · filed 2017-05-10 | $223.72K derived: sum of 3 quarters · filed 2017-05-10 | $265.99K derived: sum of 4 quarters · filed 2017-05-10 | |||||
| 2015-12-31 | $198.01K derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-16 | $208.23K derived: sum of 2 quarters · filed 2017-03-16 | $250.49K derived: sum of 3 quarters · filed 2017-03-16 | $248.19K 10-K · filed 2017-03-16 | |||||
| 2015-09-30 | $10.22K derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-09 | $52.48K derived: sum of 2 quarters · filed 2016-11-09 | $50.18K 10-Q · filed 2016-11-09 | $88.24K derived: sum of 4 quarters · filed 2017-03-16 | |||||
| 2015-06-30 | $42.26K derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-04 | $39.96K 10-Q · filed 2016-08-04 | $78.02K derived: sum of 3 quarters · filed 2017-03-16 | $72.43K derived: sum of 4 quarters · filed 2017-03-16 | |||||
| 2015-03-31 | -$2.30K 10-Q · filed 2016-05-10 | $35.76K derived: sum of 2 quarters · filed 2017-03-16 | $30.17K derived: sum of 3 quarters · filed 2017-03-16 | $71.30K derived: sum of 4 quarters · filed 2017-03-16 | |||||
| 2014-12-31 | $38.06K derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-16 | $32.47K derived: sum of 2 quarters · filed 2017-03-16 | $73.60K derived: sum of 3 quarters · filed 2017-03-16 | $85.41K 10-K · filed 2017-03-16 | |||||
| 2014-09-30 | -$5.59K derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-12 | $35.54K derived: sum of 2 quarters · filed 2015-11-12 | $47.35K 10-Q · filed 2015-11-12 | $49.63K derived: sum of 4 quarters · filed 2015-11-12 | |||||
| 2014-06-30 | $41.13K derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-06 | $52.94K 10-Q · filed 2015-08-06 | $55.22K derived: sum of 3 quarters · filed 2015-08-06 | $55.22K derived: sum of 4 quarters · filed 2015-08-06 | |||||
| 2014-03-31 | $11.81K 10-Q · filed 2015-05-07 | $14.09K derived: sum of 2 quarters · filed 2015-05-07 | $14.09K derived: sum of 3 quarters · filed 2015-05-07 | $14.09K derived: sum of 4 quarters · filed 2015-05-07 | $14.09K 10-Q · filed 2014-05-15 | ||||
| 2013-12-31 | $2.28K derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-12 | $2.28K derived: sum of 2 quarters · filed 2015-03-12 | $2.28K derived: sum of 3 quarters · filed 2015-03-12 | $2.28K 10-K · filed 2015-03-12 | $2.28K 10-K · filed 2014-03-31 | ||||
| 2013-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-13 | $0.00 derived: sum of 2 quarters · filed 2014-11-13 | $0.00 10-Q · filed 2014-11-13 | ||||||
| 2013-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-14 | $0.00 10-Q · filed 2014-08-14 | |||||||
| 2013-03-31 | $0.00 10-Q · filed 2014-05-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |